Vitamin D Supplementation for Preventing Recurrent Benign Paroxysmal Positional Vertigo: A Randomized Clinical Study.
Ann Otol Rhinol LaryngolMay 7, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)
Hussein Ali Tawfeeq, Mustafa Adnan Zaidan, Ali Kamal Ghanim
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effect of cholecalciferol supplementation on recurrent benign paroxysmal positional vertigo (BPPV) in 160 adults with vitamin D deficiency. The study found that cholecalciferol significantly reduced BPPV recurrence rates at 6, 12, 18, and 24 months compared to placebo, with a 50% relative risk reduction and a number needed to treat of 3.6.
Key findings
- Cholecalciferol increased serum 25-hydroxyvitamin D levels at 24 months (24.8 ± 3.2 vs 9.8 ± 3.6 ng/mL, P < .001).
- BPPV recurrence was reduced at 6 months (15.0% vs 35.0%, P = .004).
- At 12 months, recurrence rates were 22.5% with cholecalciferol versus 48.8% with placebo (P < .001).
- The number needed to treat to prevent one recurrence was 3.6.
Why it matters
This study highlights the potential role of vitamin D supplementation in reducing the recurrence of BPPV in patients with vitamin D deficiency, suggesting a simple intervention that could improve patient outcomes.